Clinical trial NCT01406587: Safety and Efficacy of PP4001 for the Treatment of Symptoms Associated With Uncomplicated Urinary Tract Infection
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of 50 mg, 100 mg and 200 mg PP4001 Twice Daily for the Treatment of Burning During Urination, Pain, and Urination Frequency Associated With Uncomplicated Urinary Tract Infection
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Urinary Tract Infection
Keywords: Burning
Dysuria
Frequency
Pain
Uncomplicated Urinary Tract Infection
Uncomplicated UTI
Urinary Tract Infection
UTI
Burning during urination associated with uncomplicated urinary tract infection
Urination frequency associated with uncomplicated urinary tract infection
Pain associated with uncomplicated urinary tract infection
Lead sponsor: Pinnacle Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2011-08-01
Enrollment: 261
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: PP4001 is a medication not yet approved by the US FDA. This is a phase 2, multi-center, randomized, double-blind study of 3 doses of PP4001 versus placebo in the treatment of symptoms associated with uncomplicated urinary tract infection. After the screening, patients are randomized to receive one of three doses of PP4001 or placebo. Patients are screened and randomized on the same day, and take 4 doses of study drug, one dose every 12 hours. Data about uncomplicated urinary tract infection symptoms are collected from the subjects on electronic handheld devices throughout the 48-hour study period. The primary endpoint is burning during urination.


Eligibility criteria: Inclusion Criteria:

* Female subjects must be ≥ 18 and ≤ 75 years of age at the time of consent.
* Females not of childbearing potential (FNCBP) are eligible for randomization. FNCBP are defined as postmenopausal women with their last menstrual cycle (without exogenous hormone therapy) completed more than 12 consecutive months before screening or women who are surgically sterilized (hysterectomy, oophorectomy, or tubal ligation). Females of childbearing potential also are eligible for randomization provided they are not pregnant or nursing and employ appropriate methods of contraceptives for the duration of the trial. Medically acceptable forms of contraception include abstinence, oral contraceptives, intra-uterine devices, injectable hormonals, intra-vaginal rings, or double-barrier methods (condom plus spermicide), for at least 1 month prior to treatment. Subjects in a monogamous, long term relationship with a partner who has had a vasectomy at least 3 months prior to screening are also study eligible.
* Diagnosis of uncomplicated UTI as defined by having both of the following:
* Presence of supporting symptoms including new onset (within 1 week) of urination frequency, painful urination, and/or urgency.
* Positive dipstick test for leukocyte esterase.
* Demonstration of moderate to severe burning during urination as measured by a score of at least six (6) on the 11-point rating scale for Burning During Urination during screening.
* A negative urine pregnancy test for women of childbearing potential.
* If subject has a chronic, clinically stable disease that requires medication, medication to treat that disease must be stable for at least 30 days prior to screening.
* Ability to perform study procedures, including the completion of electronic diary assessments, and supply the necessary information to the study personnel as required by the protocol.
* A signed informed consent form in which the subject agrees to participate after the study has been fully explained.

Exclusion Criteria:

* Clinically significant medical history or a clinically significant abnormal finding on the physical exam, vital signs or ECG at screening, including serious acute illness (e.g. pneumonia), gastrointestinal illness that would interfere with study drug absorption, or an untreated or unstable medical illness that would likely interfere with the study assessments.
* At risk in terms of the precautions, warnings, and contraindications in the package insert for phenazopyridine hydrochloride including:
* Known hypersensitivity to phenazopyridine hydrochloride (Defined by a history of allergic or adverse response to the drug).
* Renal failure or insufficiency (Defined as having a history of abnormal renal function or as having a known renal disease).
* History of hepatic disease or failure (Defined as having known liver disease or having elevated LFTs (\> 2 times the ULN) on previous laboratory testing. Patients who would not otherwise have such testing are not required to undergo special study labs).
* Known G-6-PD (glucose-6-phosphate dehydrogenase) deficiency.
* Prior use of a phenazopyridine product within 6 months of the first dose of study drug and throughout the study.
* Use of any prescription analgesic medication (e.g. opioids, prescription nonsteroidal anti-inflammatory drugs (NSAID), etc.) for urinary tract pain or other pain (headache, back pain, joint pain, dental pain, sore muscles, etc) within one and a half (1.5) dosing intervals for that medication before the firs dose of study drug, and throughout the study.
* Use of any systemic antibiotic within seven (7) days of study participation.
* Subjects with complaint of abnormal vaginal discharge.
* Current diagnosis or suspicion of complicated UTI or systemic infection based on one or more of the following:
* Known presence of an anatomic or functional abnormality.
* Presence of a urinary catheter.
* Infection of the urinary tract requiring an intravenous pyelogram (IVP), ultrasound or cystoscopy.
* Clinical signs of systemic infection such as fever (oral or tympanic temperature \>38 degrees Celsius), costovertebral pain or tenderness, rigors, nausea or vomiting.
* Subjects unable to comprehend the language of the informed consent and the self evaluation scales.
* Subjects who, in the opinion of the investigator, are not appropriate for, or are unable, or unwilling to undergo antibiotic treatment for uncomplicated urinary tract infection.
* Subjects with complaint of abnormal vaginal bleeding defined as different from the patient's usual menstrual period flow and timing.
* Subjects with known allergy to multivitamin or any component of the multivitamin.
* Currently participating in a clinical trial or has received an experimental drug or used an experimental device in the last 30 days prior to admission into this study.
* Subjects who, in the opinion of the investigator, are unsuitable for enrollment, unlikely to complete the course of study medication treatment, or unlikely to attend the End of Study visit.
* Subjects who are unable or unwilling to comply with the use of an electronic subject diary.
* Employees of the investigator or the institution who have direct involvement in the trial or other trials under the direction of the investigator or their associates.

Primary outcomes:
measure: To assess the efficacy of PP4001 for the relief of burning during urination as measured by the subject's self-reported score at the time of urination in women with uUTI in comparison to placebo.
timeFrame: Assessed at each urination from the time of randomization to 48 hours post first dose.
Secondary outcomes:
measure: Change from baseline in the physical exam evaluation at the End of Study visit
timeFrame: The End of Study Visit is 48 - 100 hours post first dose. SAEs will be followed up to 30 days beyond the End of Study Visit.
measure: To assess the efficacy of PP4001 for the relief of pain as measured by the subject's self-reported score at the time of urination.
timeFrame: Assessed at each urination from the time of randomization through 48 hours post first dose.
measure: To assess the efficacy of PP4001 for reduction in urination frequency as measured by the subject's self-reported void diary.
timeFrame: Assessed at each urination from the time of randomization through 48 hours post first dose.
measure: To evaluate the duration of therapeutic response to PP4001 50 mg, 100 mg and 200 mg.
timeFrame: Efficacy measures assessed in 2-hour windows after each dose.
measure: To assess global assessment of uUTI symptom severity and change over time as measured by the subject-reported global assessment diaries.
timeFrame: Assessed at each urination from the time of randomization through 48 hours post first dose.
measure: Change from baseline in vital signs at the End of Study visit
timeFrame: The End of Study Visit is 48 - 100 hours post first dose. SAEs will be followed up to 30 days after the End of Study Visit.
measure: Change from baseline in ECG at the End of Study visit
timeFrame: The End of Study Visit is 48 - 100 hours post first dose. SAEs will be followed up to 30 days beyond the End of Study Visit.
measure: Change from baseline in laboratory evaluations at the End of Study visit
timeFrame: The End of Study Visit is 48 - 100 hours post first dose. SAEs will be followed up to 30 days beyond the End of Study Visit.
measure: Frequency, severity and relationship to study medication of treatment emergent adverse events
timeFrame: From first dose through the End of Study Visit (48 - 100 hours post first dose)
Other outcomes:
Locations:
city: Montgomery
country: United States
facility: Drug Research and Analysis Corp.
state: Alabama
city: Mesa
country: United States
facility: Mesa Family Medical Center/Clincal Research Advantage
state: Arizona
city: Mesa
country: United States
facility: Desert Clinical Research/Clinical Research Advantage
state: Arizona
city: Phoenix
country: United States
facility: Central Phoenix Medical Clinic/Clinical Research Advantage
state: Arizona
city: Sacramento
country: United States
facility: Northern California Research
state: California
city: San Diego
country: United States
facility: Medical Center for Clinical Research
state: California
city: San Diego
country: United States
facility: Women's Health Care Research
state: California
city: Clearwater
country: United States
facility: Tampa Bay Medical Research
state: Florida
city: Jupiter
country: United States
facility: Health Awareness, Inc.
state: Florida
city: St. Cloud
country: United States
facility: Urology Center of Central Florida/Triquest Clinical Research Inc.
state: Florida
city: Decatur
country: United States
facility: Soapstone Center for Clinical Research
state: Georgia
city: Detroit
country: United States
facility: Hutzel Women's Health Research
state: Michigan
city: Bellevue
country: United States
facility: Bellevue Family Practice/Clinical Research Advantage
state: Nebraska
city: Las Vegas
country: United States
facility: Clinical Research Center of Nevada
state: Nevada
city: Garden City
country: United States
facility: AccuMed Research Associates
state: New York
city: Raleigh
country: United States
facility: Wake Research Associates
state: North Carolina
city: Winston-Salem
country: United States
facility: Hawthorne Medical Research, Inc.
state: North Carolina
city: Groveport
country: United States
facility: Hometown Urgent Care and Research
state: Ohio
city: Springfield
country: United States
facility: Hometown Urgent Care and Research
state: Ohio
city: Columbia
country: United States
facility: Ellipsis Research Group, LLC
state: South Carolina
city: Greenville
country: United States
facility: Palmetto Clinical Research, LLC
state: South Carolina
city: Brentwood
country: United States
facility: InvestiClin Research
state: Tennessee
city: Corpus Christi
country: United States
facility: Advanced Research Associates
state: Texas
city: Lake Jackson
country: United States
facility: R/D Clinical Research, Inc.
state: Texas
city: San Antonio
country: United States
facility: Clinical Trials of Texas
state: Texas
Study officials:
affiliation: Pinnacle Pharmaceuticals
name: Suma Krishnan
role: STUDY_DIRECTOR
References: